Across Utah County, there are people waiting for donations, whether it is a needed organ, bone marrow or blood that will save their lives. Others have given these life-saving donations to complete strangers. Gift of Life highlights those involved in the medical donation process.

They found a perfect match for Robyn Marchant on a bone marrow registry. Robyn, a Santaquin mom with leukemia, needed a stem cell transplant if she wanted to live.

But they were never able to get ahold of the match.

That was hard, Robyn said, sitting on a couch in the Huntsman Cancer Institute in Salt Lake City, next to a window that doesnt open and wearing a paisley headscarf. That was in March, at the beginning of my search.

There were two 9/10 matches on the Be The Match bone marrow registry. Doctors preferred her brothers blood work, and they decided to do the transplant with his half match. Its their best option, even if it isnt ideal.

But a lack of a match didnt stop Robyns family from hosting six drives, including ones in Provo and Spanish Fork, and adding more than 1,200 names to the bone marrow registry. They suspect theres more who have registered to Be the Match because of her, but havent used Robyns name as the promo code to link it to her name.

They might not be able to help my daughter, but I am praying there is somebody in the country who is doing the same thing to help my girl, said Shelly Bills, Robyns mother who has organized registration drives.

If Robyns transplant doesnt take, shell need another one.

And even if she doesnt need another donor from the registry, theyre hoping the names theyve added will save someone elses life.

Theres a lot of people who have never heard of the Be the Match Registry, which in all honesty we have never heard about until this happened, and now our whole town down in Santaquin knows about it, said Kevin, Robyns husband.

Diagnosis

Robyn, mom to 9-year-old Kassidy, 6-year-old Korbin, 4-year-old McKinley and 1-year-old McKellan, is a busy woman who served as a former Relief Society president for her ward in The Church of Jesus Christ of Latter-day Saints.

She started to feel really tired at the end of January and brushed it off as being worn out from having a baby. Things started to get worse to the point where shed feel like she was going to pass out when she climbed up the stairs.

It was originally thought to be anemia, but that treatment wasnt changing anything. Then her spleen started to ache.

Kevin, a pharmacist, told Robyns doctor he suspected his wife had leukemia.

Nobody expects a 31-year-old mom of four kids to get cancer, Robyn said. We were all just so overwhelmed.

She didnt ask for percentages, and only knew she wasnt going to live without a stem cell transplant.

As the oldest, Kassidy started to piece things together. The kids, who knew a neighborhood child who died after being diagnosed with cancer, were devastated.

Our kids immediately associate cancer with death, which made it hard, Kevin said.

According to Be the Match, 70 percent of patients who need a bone marrow transplant dont have a fully matched donor in their family, and 14,000 patients a year will need a transplant for someone outside their family.

For Robyn, it wasnt supposed to be hard to find someone.

The doctors at the beginning said we wont have trouble finding you a match, Robyn said. Youre Caucasian, female, of western descent, theres tons of people out there. Well find you a match. But apparently Im one in a million because we just couldnt find one.

Finding a match

Bills woke up in the middle of the night a few weeks after Robyns diagnosis knowing she had to do something.

Even though they dont plan to hold another registration drive for a while, Bills is still handing out registration kits, and a friend started the hashtag #SwabbinForRobyn.

My mind keeps saying people are so willing, they just dont know, they dont know there is something they can do to save a life, Bills said.

Shes also encouraging people already on the registry to update their contact information so another family doesnt have the same experience theyve had.

Signing up for the registry is quick process that requires a cheek swab to add a donors tissue type to the registry. Once signed up, they will remain on the registry until they are 61 or request to be removed.

Registration can be done online at Join.BeTheMatch.org. To link the registration to Robyns name, use the promo code Robyn.

Potential donors have to be between the ages of 18 and 44 and willing to donate to any patient in need.

If a match is made, there are two ways to donate. One way is through a peripheral blood stem cell donation, a nonsurgical outpatient procedure. The other is a marrow donation, a surgical, outpatient procedure that is performed in an operating room.

Only a small percentage of people on the registry will ever be called to be a match.

As she showed up to a registration drive held in a Brigham Young University LDS stake (against advice to stay away because of her compromised immune system), Robyn was touched to see hundreds of people sign up for the registry.

She didnt know a single one of them.

These kids didnt have a clue who I was, but they were willing to do something, Robyn said.

Whats next

Robyn received her brothers transplant at the end of May. Since then, shes had side effects like diarrhea, mouth sores down her throat, insomnia and nausea.

Shell be in the hospital for a couple more weeks. After that, if the transplant isnt rejected, shell have to be constantly monitored by an adult for 100 days. If all goes well, that should be it.

Her hospital room is filled with pictures of her family and has a large window that looks out to the mountain. But for now, shes not supposed to leave the unit.

Lots of pokes and prods and illnesses, I can handle that, Robyn said. But being away from my kids is hard.

She video chats with her kids at least twice a day and reads to them from the Harry Potter books before bedtime.

Shes learning to cross-stitch. Her current project, a quote from Hogwarts Headmaster Albus Dumbledore in Harry Potter and the Prisoner of Azkaban, reminds them that happiness can be found, even in the darkest of times, if one only remembers to turn on the light.

Kevin is getting help taking care of the kids from family. On weekends, they make the drive up to Salt Lake City to visit Robyn.

For now, theyre focusing on staying positive.

We are trading 2017 so we can have the rest of our lives with her, Kevin said.

Read more from the original source:
Gift of Life: Santaquin mom searching for a bone marrow match adds 1200 names to registry - Daily Herald

Bone Marrow Stem Cells Comments Off on Gift of Life: Santaquin mom searching for a bone marrow match adds 1200 names to registry – Daily Herald | June 11th, 2017

Panchwati Tower on Harmu Road in Ranchi where the stem cell bank is expected to come up. (Hardeep Singh)

In what may be a game-changer for healthcare in Jharkhand, a group of doctors from Ranchi have teamed up with a Mumbai-based pioneering research firm to plan the first stem cell bank of eastern India in the state capital.

Stem cells are undifferentiated biological cells that can differentiate into specialised cells and divide to produce more stem cells. They can be transplanted routinely to treat a variety of blood and bone marrow diseases, including cancer and immune disorders, while extensive research is underway on their potential to cure neurological and muscular problems.

In short, a stem cell bank in Ranchi will allow residents to store their embryonic or adult stem cells, which can be accessed anytime to treat ailing blood relatives.

Dr Deepak Verma, a senior orthopaedic consultant in the city specialising in difficult trauma surgery, said if everything went according to plan, the stem cell bank was expected to debut at Panchwati Tower on Harmu Road in another three to six months.

Dr Verma, along with pathologist Dr Sangita Agrawal and orthopaedic surgeon Dr S.N. Yadav, will form the core team of the Rs 6.5-crore facility, which will be set up in association with stem cell banking company ReeLabs, Mumbai.

"Ranchi will boast the fifth stem cell bank in India after Mumbai, Delhi, Chennai and Ahmedabad. It will be first such facility in eastern India. We plan to establish a stem cell treatment centre and a cancer immunotherapy centre to turn Ranchi into a healthcare destination," Dr Verma told this newspaper on Sunday.

While the bank will sprawl over an area of 5,000sqft, another 6,000sqft will be reserved for the therapy centres.

Elaborating on the banking system, the doctor said stem cells would be stored in cryogenic vials at minus 176 degrees and liquid nitrogen would be used to acquire the very low temperatures.

"People wishing to use the stem bank service will have to open an account. The bank will then collect stem cells from different sources such as placenta, amniotic sac, amniotic fluid, umbilical cord blood and cord tissue, menstrual blood, dental pulp, bone marrow and peripheral blood," Dr Verma said.

To deposit the stem cells, one may have to pay Rs 45,000 to Rs 2 lakh, depending on the package chosen.

"Those who will deposit stem cells can access the same for blood relatives suffering from 110 listed diseases that cannot be treated using conservative medicines," the doctor said, adding that stem cell therapy could help in cases of leukemia, thalassemia, Alzheimer's disease, cardiovascular diseases, stroke, diabetes and cirrhosis of liver, among others.

Do you think people in the state are aware of stem cell therapy?

Tell [emailprotected]

See the original post here:
Bank on stem cells, gift a life - Calcutta Telegraph

Bone Marrow Stem Cells Comments Off on Bank on stem cells, gift a life – Calcutta Telegraph | June 11th, 2017

Last Updated On 10 June,201705:37 pm

Stem cells can be harvested from certain parts of the human body.

(Online) - The Lipogems technology has great promise, but experts say itll take time to assess how successful the new procedure isThe technology is ideal for patients with certain orthopedic conditions, such as painful joints including the knee, ankle, or shoulder with limited range of motion. Additionally, it can be used in soft tissue defects located in tendons, ligaments, and/or muscles to improve the biologic environment, said Dr. Brian Cole, professor of orthopedic surgery, and section head of the Rush Cartilage Restoration Center, in a press release.

They are believed to help the natural regenerative processes in the body.

Hence they have earned the nickname as mini drug stores based on their ability to secrete a spectrum of bioactive molecules and support the natural regeneration of focal injuries.

Stem cells can be harvested from certain parts of the human body, most notably bone marrow and adipose tissue (fat).

Harvesting bone marrow stem cells is a significantly more invasive and time-consuming procedure that is performed using general anesthesia.

Lipogems offers a novel approach to orthopedic stem cell treatments by using a persons own fat.

The procedure uses a small incision into an area of subcutaneous fat, from which a quantity of fat tissue is harvested and processed by the Lipogems apparatus.

The technology itself, which really is the device that processes the fat, creates a concentration of fat that has been cleansed of all the extraneous things like red blood cells and fibrous tissues, Cole told Healthline.

The concentrated stem cells within that fat tissue are then applied to the problematic joint or bone area.

Lipogems offers a streamlined procedure for stem cell treatment, but there is nothing new about the science itself.

The use of stem cells to treat a variety of conditions has been ongoing for some time now.

What were lacking is really good data at this point in the clinical setting, Cole said. There is substantial data in the laboratory suggesting that these cells may function in the way Ive described: reducing inflammation and so forth. But, we really dont have yet much in the way of good solid clinical data saying that definitively this is making a difference.

Instead, he would like those seeking orthopedic treatment to understand that Lipogems is just one part of a much larger and more complex suite of tools used by physicians.

It has to be taken into context of all the other possible treatment options, from simply icing down a swollen ankle, to changing your daily activity, to surgery.

The unfortunate thing is that people think, well this is the solution that can be used instead of, say, a joint replacement and no longer do we need to do surgery, said Cole.

Nothing could be further from the truth.

Nonetheless, Cole and his team are still excited about the possibilities of the Lipogems procedure.

Using a readily available and easily accessible substance like fat as a source of stem cells could have far-reaching implications for procedures in the future.

Were optimistic and intuitively there is a good argument to be made that this is as good or better than any other source of stem cells, said Cole.

Go here to read the rest:
New technology uses body fat to help relieve joint pain - DunyaNews Pakistan

Bone Marrow Stem Cells Comments Off on New technology uses body fat to help relieve joint pain – DunyaNews Pakistan | June 10th, 2017

Updated June 09, 2017 10:59:15

Leukaemia patient Jake Cooper, 14, is desperately searching for the cure to his cancer, but his hopes of a life-saving fix now rest with strangers, not scientists.

Jake has chronic myeloid leukaemia and as his condition progresses will need a bone marrow transplant.

So why, when there are 29 million accessible donors on worldwide bone marrow registries, do so many patients, including Jake, struggle to find a match?

The answer is ethnicity, where your cultural background can turn your chance of survival into a desperate needle-in-a-haystack search.

Bone marrow transplants, sometimes called stem cell transplants, can be used to treat patients with cancers such as leukaemia, lymphoma and multiple myeloma.

But first a suitable donor needs to be found and that in itself can be a months or years-long process, one that usually starts with a patient's siblings, Red Cross bone marrow donor centre operations manager Paul Berghofer said.

"There's a one-in-four chance that [any one] sibling will be a match," he said.

While those odds aren't bad, and obviously improve if you're from a big family, they don't always deliver a match.

Then, the search broadens to the Australian Bone Marrow Donor Registry and beyond that, to a global registry, but for many patients these offer little hope.

While donors of north-west European backgrounds are over-represented on the registries, other ethnic groups are desperately under-represented.

"The chance of finding you a matched donor who is not related to you is best with people of a similar ethnic background," Mr Berghofer said.

The process wasn't drawn out but there were a bunch of general health check-ups, the initial typing and there was a discussion about the process involved.

I was told I could stop anytime up until a point of no return, I think a week or two before the transplant. You can't pull out in the last week because the [recipient] will almost certainly die.

Part of the workup is self-administering a course of an artificial hormone for five days into the flesh of my stomach. By day four or five, everything ached - like growing pains or shin splints.

The procedure itself was sitting in a chair, sticking my arms out by my side and local anaesthetic [being injected] in the crook of both elbows. To prevent damaging blood and increase the flows, they use big needles, they were ridiculous. That's why you have the anaesthetic!

Then I just lay in a chair and listened to music for four hours.

The process wasn't painful or bad, just uncomfortable and a little bit cold.

I don't regret it at all, I'd definitely do it again - it helped someone and it might be their only chance.

For Jake, whose dad is Samoan and German, and his mum Australian and British, his "incredibly rare" DNA means, despite monthly checks of the global registry, there is no bone marrow match available to tackle the "monster" in his body.

"The condition is bad enough but if it came to him [urgently] needing the transplant, I'd have to say to him, 'there's nothing I can do, we don't have a match'," his mum Renee Cooper said.

Complicating Jake's search is the fact Samoa does not have its own bone marrow registry, meaning thousands of potential matches are missed.

"It drives me crazy, there's not a day I don't think about it that someone is out there [possibly] with the cure," she said.

"The most frustrating part is I could be walking past them in a shopping centre and not even know."

Ms Cooper started Jake's Quest for a Cure on Facebook, a page she hoped would be shared to spread Jake's search around the world.

She said a lack of awareness of the registry and misinformation about the donation process were hurting patients' chances of a cure.

"There are no advertisements on bone marrow, there's no education around it in schools the way there is with organ donation," she said.

"People hear bone marrow and they think, 'oh my God, they're cutting my bones out'. People just have no idea at all."

Mr Berghofer said in 80 per cent of cases, the donation process was done as a peripheral blood stem cell collection which was not dissimilar to donating blood.

"The donor gets a needle in one arm, the blood goes through the apheresis machine and filters off blood stem cells and returns the rest of the blood back into their other arm," he said.

Pamela Bousejean, founder of Ur the Cure, an organisation striving to boost ethnic diversity on bone marrow registries, said potential donors were "slipping through our fingers everyday".

"People don't even know the bone marrow registry exists and how easy it is to donate stem cells if you're called up. You're saving a life doing something so simple," she said.

Ms Bousejean launched her campaign for a more representative registry after her own search for a donor, when she was diagnosed with Hodgkin lymphoma in 2010.

After chemotherapy and radiation treatments failed, she was told her "last chance" was to have a stem cell transplant.

"But they also told me it was going to be difficult to find me a match because of my Lebanese background," she said.

"That was really hard to hear."

For the next six months while his sister waited for a life-saving match, Ms Bousejean's brother took matters into his own hands, launching a social media campaign to find a donor.

"You're stuck in this limbo state," Ms Bousejean said.

"You know the cure to my cancer is out there in someone else's body."

In many ways, the campaign was successful raising awareness of the need for ethnic diversity on the Australian and international bone marrow registries but it didn't deliver the adult match she had been hoping for.

Instead, a "plan b" treatment in the form of a cord-blood donation gave the marketing professional her cure and she went into remission in 2012.

Now, she is on a mission to improve education programs targeted at ethnic and Indigenous communities and boost opportunities to recruit ethnically diverse bone marrow donors.

"We can make some small changes that would make a big difference," she said.

Topics: blood, diseases-and-disorders, leukaemia, perth-6000, australia

First posted June 09, 2017 06:00:36

Go here to read the rest:
Bone marrow transplants: When your heritage leads to a needle-in ... - ABC Online

Bone Marrow Stem Cells Comments Off on Bone marrow transplants: When your heritage leads to a needle-in … – ABC Online | June 10th, 2017

Stem Cell Therapy: Repair and Regenerate Our Bodies

$USRM

Stem Cells 101: The primary purpose of stem cells is to maintain, heal and regenerate tissues wherever they reside in the body. This is a continuous process that occurs inside the body throughout life. If we did not have stem cells, our lifespan would be about 1 hour, because there would be nothing to replace exhausted cells or damaged tissue.

Notably: any time the body is exposed to any sort of toxin, the inflammatory process causes stem cells to swarm the area to repair the damage.

While it is easy to think of stem cell therapy as some sort of magic, it is wise to implement strategies that nourish and optimize the stem cells we already have in your body.

Dr. Kristin Comella, a notable Stem Cell innovator, writes: You have to create an appropriate environment for these cells to function in. If you are putting garbage into your body and youre constantly burdening your body with toxins, your stem cells are getting too distracted trying to fight off those toxins. By creating an appropriate environment, optimizing your diet and reducing exposure to toxins, that will allow the stem cells that were putting in to really home in and focus on the true issue that were trying to treat.

The other thing weve discovered over the years is that [stem cell therapy] is not the type of thing where you take one dose and youre cured forever. Your tissues are constantly getting damaged Youre going to have to repeat-dose and use those stem cells to your advantage.

When you think about a lizard that loses its tail, it takes two years to grow back the tail. Why would we put unrealistic expectations on the stem cells that were trying to apply to repair or replace damaged tissue? This is a very slow process. This is something that will occur over months and may require repeat dosing.

Stem cells historically were isolated from bone marrow, and have been used for bone marrow transplants for cancer patients since the 1930s. However, we can get stem cells from just about any tissue in the body, every tissue contains stem cells.

Actually our marrow has very low amounts of mesenchymal stem cells, which are now believed to be the most important, from a therapeutic perspective.

Mesenchymal stem cells help trigger an immunomodulatory response or a paracrine effect, which means they send signals out to the rest of the body, calling cells to the area to help promote healing.

What weve discovered in more recent years is that a more plentiful source of stem cells is actually your fat tissue. [Body] fat can contain up to 500 times more cells than your bone marrow, as far as these mesenchymal type stem cells go.

One thing thats also critically important when youre talking about isolating the cells is the number of other cells that are going to be part of that population. When youre isolating a bone marrow sample, this actually is very high in white blood cells, which are pro-inflammatory, Ms. Comella writes.

White blood cells are part of the human immune response.

When an injury occurs, or a foreign body enters our system, white blood cells will attack. Unfortunately, white blood cells do not discriminate, and can create quite a bit of damage as they clean the area out.

Stem cells, in particular the mesenchymal cells, quiet down the white blood cells and then start the regeneration phase, which leads to new tissue. Bone marrow tends to be very high in white blood cells and low in the mesenchymal cells.

So, isolating stem cells from fat tissue is preferred not only because its easier on the patient, but fat also contains a higher population of mesenchymal cells and fewer white blood cells.

The benefit also of isolating [stem cells from] fat is that its a relatively simple procedure. Theres typically no shortage of fat tissue, especially in Americans, Dr.. Comella says. Also, as you age, your bone marrow declines with regards to the number of cells in it, whereas the fat tissue maintains a pretty high number of stem cells, even in older individuals.

Fat can be successfully harvested from just about anyone, regardless of their age or how thin they are. The procedure is done under local anesthesia, meaning that the patient stays awake. We can harvest as few as 15 cubic centimeters of fat, which is a very small amount of fat, and still get a very high number of stem cells.

A stem cell procedure can cost anywhere from $5,000 15,000, depending on what one is having done, and rarely if ever will insurance cover it.

Still, when compared it to the cost of long-term medications or the out-of-pocket cost of getting a knee replacement, stem cell therapy may still be a less expensive alternative.

Also, a single extraction will typically yield enough stem cells for 20 to 25 future treatments, should one decide to store his/her stem cells for future needs.

I think its accessible for patients, Dr.. Comella says. Its an out-patient procedure. You plan to be in clinic for about two hours; no real limitations afterwards, just no submerging in water, no alcohol, no smoking for a week. But other than that, patients can resume their normal activities and go about their regular daily lives.

She notes that patients who eat a very healthy diet, focusing on Organic and grass fed foods, have body fat that is very hearty and almost sticky, yielding high amounts of very healthy stem cells.

We can grow much better and faster stem cells from that fat than [the fat from] somebody who eats a grain-based diet or is exposed to a lot of toxins in their diet, she says. Their fat tends to be very fluffy, buttery yellow. The cells that come out of that are not necessarily as good a quality. Its just been very interesting. And of note, patients that are cigarette smokers, their fat is actually gray-tinged in color. The stem cells do not grow well at all.

What has been described above is whats called an autologous donation, meaning a person is getting the stem cells from oneself. A number of companies provide non-autologous donations using cells harvested from other people, typically women, like amniotic or embryonic mesenchymal cells.

This is an important distinction.

There are now just a couple of studies that have been published comparing an autologous source, meaning cells from you own body, to an allogeneic source, meaning cells from someone else.

So far, what has been discovered is that the autologous cells will outperform somebody elses cells inside ones body. This is not fully understood yet. It may be that the environment that ones own cells function in, and that they used to that environment. They recognize it. It is the same DNA and they can function well there.

But, once the culture is expanded and a pure population of these mesenchymal cells, not necessarily the sample thats coming right off of the liposuction, but a sample that has been taken to the lab and grown, those cells will not elicit an immune response if you use them in someone else. You could scientifically and medically use those in an unmatched person. However, there are some regulatory aspects of that with regards to the FDA.

In the US, there are a variety of new stem cell products available, referred to as amniotic, cord blood products or placenta products, which are prepared at a tissue bank. Such facilities must be registered with the FDA, and the products must undergo additional processing.

For example, they must be morselized, or snap frozen or blended in some way. Such processing typically breaks the membrane, releasing growth factors, and the resulting products are called acellular, meaning there are no living cells remaining in the sample.

The amniotic products available in the US are not so much stem cell products as they are growth factor products.

Dr. Comella notes: They can be useful in creating an immunomodulatory response, which can help to promote healing, but that still differs from the living stem cell procedures that can be done by either isolating cells from your fat or bone marrow. As a general rule, you do not achieve the clinical benefits when using an amniotic product, primarily because they do not contain living stem cells.

I want to contrast that to what are called embryonic stem cells, Dr. Comella adds. The products obtained from cord blood, from women who are having babies, are not embryonic stem cells. Embryonic stem cells are when you are first bringing the egg and sperm together. Three days after that, you can isolate what is called an inner cell mass. This inner cell mass can be used to then grow cells in culture, or that inner cell mass could eventually lead to the formation of a baby.

Those are embryonic stem cells, and those are pluripotential, meaning that they have the ability to form an entire being, versus adult stem cells or stem cells that are present in amniotic tissue, [which] are multipotential, which only have the ability to form subsets of tissue.

When youre dealing with different diseases or damaged tissue or inflammation, mostly you want to repair tissue. If somebody has damage in their knee, they dont necessarily need embryonic cells because they dont need a baby in their knee. They need new cartilage in their knee.

A common question is whether stem cells can cause overgrowth, leading to cancer or tumor formation.

As noted by Dr. Comella, this is a problem associated with embryonic stem cells, which tend to grow very rapidly and can form a teratoma because of the rapid cell growth. Adult stem cells, the cells obtained from ones own body, have growth inhibitions and will not form teratomas.

The theoretical concern that has been addressed in animal models or in petri dishes is that if you take cancer cells that are growing in a dish and apply stem cells, it may make those cancer cells grow more rapidly. But this does not translate in-vivo to humans.

If there was truly an issue with applying stem cells to a patient who has cancer, we would know about it by now, because weve been dosing cancer patients with stem cells since the 1930s. The safety profile is strong and there are tens of thousands of patients documented with these treatments, Dr. Comella says.

Another useful therapy is platelet-rich plasma (PRP).

Our peripheral blood contains platelets, which act as 1st responders when theres an injury. They come in and start the clotting mechanism, thereby preventing one from bleeding to death. They also give marching orders to other cells.

For example: platelets can command stem cells to multiply and grow, or to differentiate and form new tissue.

These platelets also have many different growth factors associated with them, which can help to promote healing and stop inflammation. PRP involves taking a blood sample and then spinning the blood in a centrifuge to isolate the platelets. The platelet-rich plasma is then injected back into the area that is inflamed.

One of the most common uses of platelet-rich plasma or PRP is in a joint. Now, platelets are going to be most successful in something that is rich in stem cells [such as] an acute or a very recent injury.

If you just hurt your knee, the first thing you should do is get PRP, because its going to help promote healing, and those platelets will attach to the surface receptors of the stem cells that are already going to the area to promote healing. It would be like putting fertilizer on your seed, which are the stem cells.

If you have something more chronic, this tends to be a stem cell-poor environment. In other words, you have osteoarthritis or youve got knee pain thats 5 years old and its been there for a long time; just putting PRP in it would be like putting fertilizer on dirt without planting a seed first.

The beauty of stem cell therapy is that it mimics a process that is ongoing in the human body all the time. Our stem cells are continuously promoting healing, and they do not have to be manipulated in any way. The stem cells naturally know how to home in on areas of inflammation and how to repair damaged tissue.

All were doing is harnessing the cells from one location where theyre sitting dormant and relocating them to exactly where we want them and we need them to work, Dr. Comella says. Basically, anything inside your body that is inflamed, that is damaged in some way, that is lacking blood supply, the [stem] cells can successfully treat.

That means orthopedics, knee injections, shoulder injections, osteoarthritis, acute injuries, anterior cruciate ligament tears in the back, back pain associated with degenerative disc disease or damaged tendons or ligaments, herniated and bulging discs. You can also use it in systemic issues, everything from diabetes, to cardiac, to lungs, any tissue organ inside your body that has been damaged.

Autoimmune diseases can also be treated. The stem cells are naturally immunosuppressant, meaning they can help quiet down an over reactive immune system and help the immune system function in a more normal way. Neurological diseases, traumatic brain injury, amyotrophic lateral sclerosis, Parkinsons. All of these have to do with tissue thats not functioning properly. The cells can be used to address that.

It is very impressive, the list of different diseases that could benefit from this intervention.

Again, it is not magic, but one can dramatically improve the benefits of this intervention by combining it with other healthy lifestyle factors that optimize mitochondrial function, such as eating a healthy Real food diet, exercising, sleeping well, avoiding toxins and detoxifying from toxic influences.

Stem Cells for Anti-Aging: Stem cells can also be used as part of an anti-aging program.

Dr. Comella has used stem cells on herself for several years, and report feeling better now than she did 10 year ago.

She writes,The ability to reduce inflammation inside your body is basically making yourself live longer. Inflammation is what kills us all. Its what makes our telomeres shrink. Its what causes us pain and discomfort. Its what makes the tissues start to die. The ability to dose yourself with stem cells and bring down your inflammation, which is most likely caused by any sort of toxin that youve been exposed to, breathing air is exposure to toxins, this is going to lengthen your lifespan.

I typically will do a dose every six to 12 months, regardless of whats going on. If I have anything that is bothering me, if I tweak my knee at the gym, then I absolutely will come in and do an injection in my knee. I want to keep my tissue healthy for as long as possible.

I want to stay strong. I dont want to wait until something is wrong with me. I think that this is the future of medicine. This is what were going to start to see. People will begin to get their regular doses of [their own] stem cells and itll just be common practice.

Keep in mind theres a gradual and progressive decline in the quality and the number of stem cells as we age, so if considering this approach, it would be to your advantage to extract and bank your stem cells as early on as possible. US Stem Cell provides a stem cell bank service, so one can store them until a later date when you might need them.

Your stem cells are never as young as they are right now. Every minute that you live, your telomeres are shrinking. The ability to lock in the youth of your cells today can be very beneficial for you going forward, and for your health going forward. God forbid something happens. What if you have a heart attack? Youre not going to get clearance to get a mini-lipo aspirate procedure.

If you have your cells waiting in the bank, ready for you, it becomes very easy to pull a dose and do an IV delivery of cells. Its almost criminal that were not doing this for every single one of our cardiac patients. This should be standard practice. We should be having every single patient bank their stem cells at a young age and have them waiting, ready and available. The technology is there. We have it. Im not sure why this technology is not being made available to everyone, she says.

I think stem cell therapy is very different than traditional medicine. Stem cell therapy may actually make it so that you dont have to be dependent on pharmaceutical medications. You can actually repair the tissue and thats it. This is a very different way of viewing medicine.

For a Physician in your area providing the service, you can go there. US Stem Cell can help you locate a qualified doctor.

Eat healthy, Be healthy, Live lively

blood, bodies, body, cell, cells, damage, grow, help, knee, patients, regenerate, repair, stem, tissue, USRM

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of The Red Roadmasters Technical Report on the US Major Market Indices, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

See the original post:
Stem Cell Therapy: Repair and Regenerate Our Bodies - Live Trading News

Bone Marrow Stem Cells Comments Off on Stem Cell Therapy: Repair and Regenerate Our Bodies – Live Trading News | June 9th, 2017

The Lipogems technology has great promise, but experts say itll take time to assess how successful the new procedure is.

What if you could put that little bit of body fat around your midsection to good use?

A procedure called Lipogems utilizes a persons body fat as a source of stem cells to help treat arthritis and joint conditions.

At least thats the promise.

Lipogems was approved for widespread use by the Food and Drug Administration (FDA) in November 2016, and its already garnering a lot of attention.

Rush University Medical Center recently became the first sports medicine specialists in the Midwest to offer treatment with the device.

The technology is ideal for patients with certain orthopedic conditions, such as painful joints including the knee, ankle, or shoulder with limited range of motion. Additionally, it can be used in soft tissue defects located in tendons, ligaments, and/or muscles to improve the biologic environment, said Dr. Brian Cole, professor of orthopedic surgery, and section head of the Rush Cartilage Restoration Center, in a press release.

Read more: Stem cell therapies offering hope for MS patients

Stem cells work by growing and differentiating themselves into different cells in the body based on the site of injection.

They are believed to help the natural regenerative processes in the body.

Hence they have earned the nickname as mini drug stores based on their ability to secrete a spectrum of bioactive molecules and support the natural regeneration of focal injuries.

Stem cells can be harvested from certain parts of the human body, most notably bone marrow and adipose tissue (fat).

Harvesting bone marrow stem cells is a significantly more invasive and time-consuming procedure that is performed using general anesthesia.

Lipogems offers a novel approach to orthopedic stem cell treatments by using a persons own fat.

The procedure uses a small incision into an area of subcutaneous fat, from which a quantity of fat tissue is harvested and processed by the Lipogems apparatus.

The technology itself, which really is the device that processes the fat, creates a concentration of fat that has been cleansed of all the extraneous things like red blood cells and fibrous tissues, Cole told Healthline.

The concentrated stem cells within that fat tissue are then applied to the problematic joint or bone area.

The procedure can be completed in under 30 minutes.

Read more: Stem cell therapy a possible treatment for rheumatoid arthritis

Lipogems offers a streamlined procedure for stem cell treatment, but there is nothing new about the science itself.

The use of stem cells to treat a variety of conditions has been ongoing for some time now.

As Healthline reported earlier this year, stem cells have been touted as a breakthrough treatment for some time, but real proof of efficacy is still being researched.

The same is true for Lipogems.

What were lacking is really good data at this point in the clinical setting, Cole said. There is substantial data in the laboratory suggesting that these cells may function in the way Ive described: reducing inflammation and so forth. But, we really dont have yet much in the way of good solid clinical data saying that definitively this is making a difference.

He further cautions individuals thinking that the new procedure, or that stem cells in general, are a panacea.

Read more: Unproven stem cell treatments offer hope but also risks

Instead, he would like those seeking orthopedic treatment to understand that Lipogems is just one part of a much larger and more complex suite of tools used by physicians.

It has to be taken into context of all the other possible treatment options, from simply icing down a swollen ankle, to changing your daily activity, to surgery.

The unfortunate thing is that people think, well this is the solution that can be used instead of, say, a joint replacement and no longer do we need to do surgery, said Cole.

Nothing could be further from the truth.

Nonetheless, Cole and his team are still excited about the possibilities of the Lipogems procedure.

Using a readily available and easily accessible substance like fat as a source of stem cells could have far-reaching implications for procedures in the future.

Were optimistic and intuitively there is a good argument to be made that this is as good or better than any other source of stem cells, said Cole.

Go here to see the original:
New Technology Uses Body Fat to Help Relieve Joint Pain - Healthline

Bone Marrow Stem Cells Comments Off on New Technology Uses Body Fat to Help Relieve Joint Pain – Healthline | June 9th, 2017

The BMT program at MedStar Georgetown is a joint effort with specialists from John Theurer Cancer Center and a key component of the Lombardi Comprehensive Cancer Center, the only cancer program in the Washington, D.C. region designated by the National Cancer Institute (NCI) as a comprehensive cancer center.

"Once considered experimental, BMT is today's established gold standard for treating patients with a number of malignant and other non-malignant diseases of the immune system, blood, and bone marrow, including multiple myeloma, lymphoma, and acute and chronic leukemia. For some conditions, blood stem cell transplant can provide a cure in patients who have failed conventional therapies," says Scott Rowley, M.D., chief of the BMT program at MedStar Georgetown as well as a member of the John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation. "For some conditions, it can actually be a cure; for others, it prolongs survival and improves quality of life. Having performed 100 BMTs at MedStar Georgetown including allogenic transplantation illustrates the strength and maturity of our program achieved in rather short time."

MedStar Georgetown's program is also the only comprehensive BMT center within Washington, D.C. and southern Maryland with accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) for adult autologous procedures, where the patient donates his or her own cells.

The BMT program at John Theurer Cancer Center is one of the top 10 transplant programs in the United States, with more than 400 transplants performed annually.

A BMT involves a two-step process: first, collecting bone marrow stem cells from the patient and storing them for future use. Then, a week or so later, patients receive high dose chemotherapy to eliminate their disease. The previously stored cells are reinfused back into the bloodstream, where after reaching the bone marrow, they begin repopulating and allow the patient to recover their blood counts over the following 2 weeks.

"Even though BMT is considered standard therapy for myeloma worldwide, in the United States fewer than 50 percent of the patients who could benefit from BMT are referred for evaluation," says David H. Vesole, M.D., Ph.D., co- chief and director of Research of John Theurer Cancer Center's Multiple Myeloma division and director of MedStar Georgetown's Multiple Myeloma Program.

"That's mostly due to physicians' concerns that a patient is too old or compromised from other health conditions like diabetes, cardiac disease or renal failure. But new techniques and better supportive care have improved both patient outcomes and the entire transplant process, extending BMT to more patients than ever before."

The MedStar Georgetown/Georgetown Lombardi Blood and Marrow Stem Cell Transplant Program is part of a collaborative cancer research agenda and multi-year plan to form an NCI-recognized cancer consortium. This recognition would support the scientific excellence of the two centers and highlight their capability to integrate multidisciplinary, collaborative research approaches to focus on all the aspects of cancer.

The research areas include expansion of clinical bone marrow transplant research; clinical study of "haplo" transplants use of half-matched stem cell donor cells; re-engineering the function and focus of key immune cells; and the investigation of "immune checkpoint" blocking antibodies that unleash a sustained immune response against cancer cells.

"In this partnership, we've combined John Theurer's strength in clinical care with Georgetown Lombardi's strong research base that significantly contributes to clinical excellence at MedStar Georgetown. By working together, we have broadened our cancer research to offer more effective treatment options for tomorrow's patients," says Andrew Pecora, M.D., FACP, CPE, president of the Physician Enterprise and chief innovations officer, Hackensack Meridian Health. "This is one of many clinical and research areas that have been enhanced by this affiliation."

"Our teams are pursuing specific joint research projects we feel are of the utmost importance and significance in oncology particularly around immuno-oncology as well as precision medicine," says Andr Goy, M.D., MS, chairman of the John Theurer Cancer Center and director of the division chief of Lymphoma; chief science officer and director of Research and Innovation, RCCA; professor of medicine, Georgetown University. "Together our institutions have a tremendous opportunity to transform the delivery of cancer care for our patient populations and beyond."

ABOUT THE JOHN THEURER CANCER CENTER AT HACKENSACK UNIVERSITY MEDICAL CENTER John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish the John Theurer Cancer Center from other facilities.www.jtcancercenter.org.

ABOUT MEDSTAR GEORGETOWN UNIVERSITY HOSPITAL MedStar Georgetown University Hospital is a not-for-profit, acute-care teaching and research hospital with 609 beds located in Northwest Washington, D.C. Founded in the Jesuit principle of cura personaliscaring for the whole personMedStar Georgetown is committed to offering a variety of innovative diagnostic and treatment options within a trusting and compassionate environment. MedStar Georgetown's centers of excellence include neurosciences, transplant, cancer and gastroenterology. Along with Magnet nurses, internationally recognized physicians, advanced research and cutting-edge technologies, MedStar Georgetown's healthcare professionals have a reputation for medical excellence and leadership. For more information please visit: medstargeorgetown.org/bmsct

ABOUT HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER Hackensack Meridian Health Hackensack University Medical Center, a 775-bed nonprofit teaching and research hospital located in Bergen County, NJ, is the largest provider of inpatient and outpatient services in the state. Founded in 1888 as the county's first hospital, it is now part of one of the largest networks in the state comprised of 28,000 team members and more than 6,000 physicians. Hackensack University Medical Center was listed as the number one hospital in New Jersey in U.S. News & World Report's 2016-17 Best Hospital rankings - maintaining its place atop the NJ rankings since the rating system was introduced. It was also named one of the top four New York Metro Area hospitals. Hackensack University Medical Center is one of only five major academic medical centers in the nation to receive Healthgrades America's 50 Best Hospitals Award for five or more years in a row. Becker's Hospital Review recognized Hackensack University Medical Center as one of the 100 Great Hospitals in America 2017. The medical center is one of the top 25 green hospitals in the country according to Practice Greenhealth, and received 25 Gold Seals of Approval by The Joint Commission more than any other hospital in the country. It was the first hospital in New Jersey and second in the nation to become a Magnet recognized hospital for nursing excellence; receiving its fifth consecutive designation in 2014. Hackensack University Medical Center has created an entire campus of award-winning care, including: the John Theurer Cancer Center; the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Women's and Children's Pavilion, which houses the Joseph M. Sanzari Children's Hospital and Donna A. Sanzari Women's Hospital, which was designed with The Deirdre Imus Environmental Health Center and listed on the Green Guide's list of Top 10 Green Hospitals in the U.S. Hackensack University Medical Center is the Hometown Hospital of the New York Giants and the New York Red Bulls and is Official Medical Services Provider to The Northern Trust PGA Golf Tournament. It remains committed to its community through fundraising and community events especially the Tackle Kids Cancer Campaign providing much needed research at the Children's Cancer Institute housed at the Joseph M. Sanzari Children's Hospital. To learn more, visit http://www.HackensackUMC.org.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/john-theurer-cancer-center-and-medstar-georgetown-university-hospital-announce-100th-blood-stem-cell-transplant-300471445.html

SOURCE Hackensack Meridian Health

Continue reading here:
John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100th Blood Stem Cell Transplant - PR Newswire (press release)

Bone Marrow Stem Cells Comments Off on John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100th Blood Stem Cell Transplant – PR Newswire (press release) | June 9th, 2017

Xconomy Boston

If youve donated blood, you probably received a follow-up message asking you to consider a platelet donation. Donation centers must constantly replenish their blood supplies, but the need for platelets is particularly acute. Compared to other components of blood, platelets are fragile and short lived, which puts high demand on the small supply of these cell fragments that are key to stopping bleeding.

Plasma separated from blood can be frozen and red blood cells can be refrigerated for up to 42 days. But platelets, which must be stored at room temperature, last just five days. After pathogen screening and transport, platelets have about two days to reach a patient, says Sven Karlsson, president and co-founder of Boston-based Platelet Biogenesis.

Karlssons startup aims to bring hospitals an alternative: platelets produced as needed from stem cells. Platelet BioGenesis, a spinout from Harvard University and Brigham and Womens Hospital, now has $10 million from a Series A round of funding to support preclinical testing of its regenerative medicine technology.

The body produces the components of blood in bone marrow. Platelets are made by a type of bone marrow cell called a megakaryocyte. Platelet Biogenesis produces its platelets in a two-step process. It first develops megakaryocytes from stem cells in culture, Karlsson says. Next, the megakaryocytes are fed into a device that the company developed that puts the cells through a process the company says is similar to what occurs in natural bone marrow physiology and results in the production of platelets.

Were making real, functional platelets, Karlsson says. Instead of mimicking the platelet, were mimicking the process of making a platelet.

Platelet transfusions are needed by patients whose bodies dont produce enough platelets, as well as those who have clotting problems. These transfusions are also used to treat patients who have cancer or are undergoing surgery. Since most platelet donation centers are in urban areas, the short shelf life of platelets makes supplies tight in rural areas. Donations dont entirely solve the problem, Karlsson says. While donating whole blood takes about 15 minutes, platelet donation takes 90 minutes, which makes it harder to get donors.

Researchers have tried to address the platelet shortage problem by developing synthetic platelets. But Karlsson says that the synthetic versions can cause side effects. The idea for replicating the bodys process of producing platelets stems from more than a decade of research. Jonathan Thon, the CEO and co-founder of Platelet BioGenesis, was pursuing ways to extend the shelf life of platelets. But Karlsson says Thon concluded a better approach might be developing a way to replace human donors. As a post-doctoral researcher at Harvard, he invented a microfluidic device that mimics a human bone marrow.

Before Platelet BioGenesis can bring its platelet-making technology to the market, it will need FDA approval. The regulator treats blood products as therapeutics, which means that the company will need to conduct clinical trials. Karlsson says the funding round will support preclinical research. Within three years, he expects the startup will be able to start Phase 1 safety studies. For those trials, Platelet BioGenesis will need to raise additional funds. The current financing round was led by Qiming US Healthcare Fund and included participation from Vivo Capital, VI Ventures, Adena Partners, eCoast Angels, as well as other unidentified investors.

If Platelet BioGenesis wins FDA approval, Karlsson says the company plans to become a manufacturer, selling its platelets in the existing blood supply chain. Its early to talk about pricing, but he says that Platelet Biogenesis products could be more affordable because they are produced from a pathogen-free source. They could also be produced on demand. While the startups platelets should have the same shelf-life as platelets from human donors, Karlsson says that the parent cells that produce platelets can be stored frozen. When platelets are needed, thawed cells can be placed in the companys microfluidic device, which produces platelets within hours.

Karlsson says Platelet BioGenesis might be able offer another advantage: beating the five-day shelf life of donor platelets. In the body, a platelet lasts 10 days. If all of Platelet BioGenesis platelets are born on the same day, they should theoretically have the same 10-day life, he says. Thats one of the things the company plans to test in upcoming trials. The company will also evaluate its platelets to make sure that they are comparable to donor platelets.

Imageby Wikimedia user Erhabor Osarovia a Creative Commons license.

Frank Vinluan is editor of Xconomy Raleigh-Durham, based in Research Triangle Park. You can reach him at fvinluan [at] xconomy.com

See more here:
Harvard Biotech Spinout Lands $10M to Make Platelets From Stem Cells - Xconomy

Bone Marrow Stem Cells Comments Off on Harvard Biotech Spinout Lands $10M to Make Platelets From Stem Cells – Xconomy | June 8th, 2017

Patients with rare blood cancer brought back to normal - The Hindu The Hindu Undergo bone marrow transplant at Apollo Cancer Institute. and more »

See the original post:
Patients with rare blood cancer brought back to normal - The Hindu - The Hindu

Bone Marrow Stem Cells Comments Off on Patients with rare blood cancer brought back to normal – The Hindu – The Hindu | June 8th, 2017

This week alone in the news weve seen air strikes, suicide bombings and murders caused by hate. Violence over the hue of someones skin, the way they speak or how they dress. Hate-filled speech by neighbors at meetings and on Facebook. At dinner yesterday, my 8-year-old step-daughter asked her dad, Whats a bomb? My heart is heavy.

Its easy to forget that we are more alike than we are unalike. I offer to you a different perspective.

Six years ago my brother got the call he had Hodgkin Lymphoma, a cancer that starts in cells that are part of the bodys immune system. He was 28 years old. It started as a visible lump under his collar bone, and sometimes you wonder how can so much suffering be caused by such a little lump? And so my story begins.

About one year into his treatment, he reached remission, and from there he was required to undergo an autologous stem cell transplant (a transplant using his own stem cells) to replace his bone marrow and stem cells that were destroyed by chemotherapy and radiation. Fast-forward 10 or so months and my brothers cancer returned. This time the treatment plan had to change his body needed help actually fighting the cancer cells, rather than just a replenishment of normal blood cells. This time around, he required an allogeneic stem cell transplant (a transplant using the stem cells from a healthy donor) and as his sister, I needed to be tested to see if I was a tissue match.

This was all new to me and our family. You hear a lot about cancer. We all know someone who has it, if you dont have cancer yourself. But I knew nothing about stem cell transplants or what it meant to be a donor. First we had to find out if my brother and I were a match.

I received a kit in the mail and all I had to do was swab the inside of my cheek, place the swab inside a sealed bag, and mail it back to the hospital. A week or so later, my brother got the news from his doctor that changed our lives. I was, in fact, a match a near perfect match and we could move forward with his second stem cell transplant.

At this point in my story, youre probably thinking, Of course, youd be a match, youre his sister. I assumed so, as well. Read on.

On Aug. 12, 2016, my brother and I underwent our stem cell transplant at Dana Farber/Brigham and Womens Hospital in Boston. There are two different ways to donate stem cells peripheral blood stem cells (stem cells extracted from your blood after receiving five days of injections of a drug called filgrastim, used to increase the number of blood-forming cells in your bloodstream) and bone marrow (a surgical procedure where doctors use needles to withdraw liquid marrow from both sides of the back of your pelvic bone). Due to my brothers specific treatment plan, he required pure bone marrow, and my bone marrow was taken from my pelvis. Two liters worth of my bone marrow was processed at Dana Farber and then brought to my brother immediately, who received it via an IV drip.

So how does my story end? Why am I telling you all this?

My brother is thriving. My pelvis has healed. And we were absolutely blessed to find a match right within our family.

The reality is that fewer than 30 percent of patients with a blood cancer or blood disease will find a related-donor; the other 70 percent, thousands of patients with blood cancers like leukemia and lymphoma, sickle cell anemia or other life-threatening diseases, depend on the national bone marrow registry to find a match to save their life. Some day you or someone you love might depend on a complete stranger who might be a Muslim, a Republican, gay or straight. But it wont matter because from the inside, they will be the same.

I plead with you to remember that we are more alike than we are unalike, and to do something positive for humanity.

You can visit http://www.bethematch.org and join the Be The Match national bone marrow registry.

Or you can attend one of my in-person donor drives in Greenfield over the next few months. The first will be this Saturday, June 10, from 2 to 4 p.m. at the Pints in the Park event at the Greenfield Energy Park.

If you are between the ages of 18 and 44, patients especially need you. You could be someones cure.

I note the obvious differences

between each sort and type,

but we are more alike, my friends,

than we are unalike.

We are more alike, my friends,

than we are unalike.

From Human Family, a poem by Maya Angelou

Ashli Stempel is a Greenfield resident and a member of the Greenfield Town Council.

Excerpt from:
My Turn: Do something within your power to save another life - The Recorder

Bone Marrow Stem Cells Comments Off on My Turn: Do something within your power to save another life – The Recorder | June 8th, 2017

June 8, 2017 One example of STAT1 GOF Mutation phenotype. Credit: Hiroshima University

Researchers report the first-ever study assessing how patients with "gain of function" mutation of the STAT1 gene respond to stem cell transplantation. It involved 15 young patients from nine different countries, each suffering a range of complications caused by the gene's mutation.

Of these, only six survived a regime of stem cell transplantationwith five completely cured and disease free by the study's conclusion.

The study was carried out by Dr. Satoshi Okada (Hiroshima University), Professor Jennifer Leiding (University of Florida), Professor Tomohiro Morio (Tokyo Medical and Dental University), and Professor Troy Torgerson (University of Washington).

Dr. Okada, who first discovered the STAT1 gain of function mutation in 2011, says, "Overall, this result is disappointing but the fact that five patients were cured proves that treatment with stem cells can work, and we now need to learn from these 15 individual cases."

The STAT1 gene plays a vital role in the body's immune system. Rare mutations can lead to STAT1's over-activation (GOF) and autoimmunity.

While the majority of patients afflicted typically show mild to moderate symptoms involving fungal (mostly Candida), bacterial, and viral infectionsabout 10 percent of cases are severe and life threatening.

Until now, developing suitable treatments has been challenging; e.g. anti-fungal drugs temporarily treat the symptoms but not the source mutation, and immunosuppressive therapies often do more harm than good by knocking out already overburdened immune systems.

With only one confirmed case prior to this study of a sufferer being successfully cured using stem cell transplantation, researchers are keen to build an understanding of best practices in order to offer real hope for the typically young sufferers of this condition.

The 15 selected patients were sourced via an international appeal to transplant centers and consortiums. Their ages ranged from 13 months to 33 years at the time of treatment. Screening by HU researchers confirmed that each had the STAT1-GOF mutation, and that the mutation was the source of their ailments.

Treatment was carried out independently by centers around the world. It used chemotherapy to eradicate the host's bone marrowthe source of the damaging STAT1 mutation in these patients. Healthy stem cell cultures sourced from donors were then transplanted into the subjects with the aim of reconstituting their bone marrow to a mutation-free, disease-fighting state.

The researchers suspect three reasons for the low 40 percent success rate:

In response, the researchers have made several proposals for improving this treatment. Due to most of the patients having mild to moderate ailments, only those suffering from severe symptoms should undergo this treatment. In addition, the chemotherapy dosage should be reduced. Those who received low-dose chemotherapy reacted better.

However, a balance must be struck. Low-dose chemotherapy may not eradicate host bone marrow to the extent required for its reconditioning the chance of transplant rejection is thus increased. With this in mind, support treatment may be required to neutralize host antibodies and prevent attacks of introduced stem cells.

Finally, due to the relative success seen in younger patients, stem cell transplantation should occur at as early an age as possible. Due to recent advancements in STAT1-GOF diagnosis, early detection is now a very real possibility hopefully leading to greater success rates, and less suffering for those carrying this potentially devastating mutation.

Explore further: 'Smart' genetic library makes disease diagnosis easier

More information: Jennifer W. Leiding et al. Hematopoietic stem cell transplantation in patients with Gain of Function STAT1 Mutation, Journal of Allergy and Clinical Immunology (2017). DOI: 10.1016/j.jaci.2017.03.049

Researchers at Hiroshima University have developed a smart genetic reference library for locating and weeding out disease-causing mutations in populations.

A single blood test and basic information about a patient's medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant ...

UCLA researchers have developed a stem cell gene therapy cure for babies born with adenosine deaminase-deficient severe combined immunodeficiency, a rare and life-threatening condition that can be fatal within the first year ...

Physicians at the University of Illinois Hospital & Health Sciences System have cured 12 adult patients of sickle cell disease using a unique procedure for stem cell transplantation from healthy, tissue-matched siblings.

Using a technique that avoids the use of high-dose chemotherapy and radiation in preparation for a stem cell transplant, physicians at the University of Illinois Hospital & Health Sciences System have documented the first ...

A large, nationwide study published in the journal JAMA Oncology found that people who received transplants of cells collected from a donor's bone marrow the original source for blood stem cell transplants, developed decades ...

In news that may bring hope to asthma sufferers, scientists discover a mechanism that provides a possible new target for allergy treatments.

(HealthDay)Administration of allergen immunotherapy (AIT) in patients with allergic asthma leads to lower short-term symptom and medication scores, according to a review published online May 19 in Allergy.

A single treatment giving life-long protection from severe allergies such as asthma could be made possible by immunology research at The University of Queensland.

Malaria caused by Plasmodium parasites is a life-threatening infectious disease that kills at least half a million people annually while causing over 200 million new infections. In some cases, complications can quickly develop ...

Virtually the entire population of sub-Saharan Africa, and some 70% of African Americans, carry a gene variant (allele) which results in a trait referred to as Duffy-negative. It has long been known that carriers of this ...

Immunotherapy drugs to combat cancer have stimulated tremendous excitement among patients and physicians alike. They debuted in 2011, when the U.S. Food and Drug Administration approved ipilimumab (Yervoy) to treat metastatic ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more:
Stem cell treatment for lethal STAT1 gene mutation produces mixed results - Medical Xpress

Bone Marrow Stem Cells Comments Off on Stem cell treatment for lethal STAT1 gene mutation produces mixed results – Medical Xpress | June 8th, 2017

June 6, 2017 Drs. Carlos Isales, Meghan McGee-Lawrence, William D. Hill and Mark Hamrick. Credit: Phil Jones

With age, the form and function of our bones and muscles drop off, putting us as increased risk for frailty and falls.

Now researchers at the Medical College of Georgia at Augusta University are dissecting just what happens to the stem cells that make the tissues, which help keep us upright, with an eye on improving our healthspan.

Osteoporosis already is a major public health problem affecting about 44 million Americans and costing billions annually. The world's older population is growing at an unprecedented rate with 8.5 percent of the worldwide population - 617 million people - age 65 and older, a proportion estimated to reach 17 percent by 2050, according to the National Institute on Aging.

"After age 65 you start losing about 1 percent of both muscle and bone per year," said Dr. Carlos Isales, endocrinologist, Regents' professor and vice chair for clinical affairs in the MCG Department of Neuroscience and Regenerative Medicine.

"Daily exercise decreases the slope of that decline. But what we are focusing on is trying to see if we can flatten the curve even further," said Isales, principal investigator on a new $9.3 million Program Project grant from the National Institutes of Health.

Time seems to alter the dynamic between the mesenchymal stem cells making bone and muscle and the amino acids that fuel them. The MCG scientists also have evidence it changes the signals stem cells send each other.

The bottom line: Our stem cell population gets reduced and the cells we have become less efficient at making bone and muscle, often opting for the easier task of making fat instead, Isales said.

The team, which includes principal investigators bone biologist Dr. Mark Hamrick, stem cell researcher Dr. William D. Hill and biomedical engineer Dr. Meghan McGee-Lawrence, wants to keep stem cells focused on making bone and muscle.

"We are looking at stem cells as a group and what is happening to them as we age," Hill noted. "This includes a loss of direction so they aren't as functional as they were before. The other thing we are looking at is their survival and their numbers."

"We are trying to figure out why the changes are happening and if we can target those cells to make them want to make bone again," McGee-Lawrence said.

Much as the function of bone and muscle is interwoven, so is their health and the factors that promote their loss or survival also are similar, said Hamrick.

A major culprit in their breakdown appears to be the metabolite kynurenine, a byproduct of the essential amino acid tryptophan. Tryptophan is among the nine amino acids our body can't make and we must consume in foods like turkey and soybeans so we can perform essentials like making protein. The researchers also think the fuel sends signals to cells, ones that aging stem cells apparently don't get.

The unhealthy metabolite is the result of a natural action called oxidation, which occurs anytime cells use oxygen. Particularly with age, the free radicals produced by oxidation can also damage cells. Kynurenine results when the enzyme, indoleamine 2,3 dioxygenase, or IDO, which a variety of tissues make to help moderate an immune response, oxidizes tryptophan. Over time, kynurenine piles up and appears to alter the dynamic of bone and muscle formation.

Again, somewhat ironically, the many functions of essential amino acids include working as antioxidants, so the researchers are putting together nutrient cocktails - minus tryptophan and with reduced protein content - that they hope can reverse age-related damage. Isales notes that they may find that other amino acids produce similar problems as tryptophan in the aged environment.

So they also are taking more direct approaches like whether an IDO inhibitor - which is already in clinical trials as a cancer fighter - can reverse changes and get stem cells to regain more youthful function.

In an effort to begin to see if what they have seen in laboratory mice holds up in humans, they are trying both approaches in human stem cells retrieved during the process of a knee or hip replacement by colleagues in the MCG Department of Orthopaedic Surgery.

They have laboratory evidence that in mice at least, high kynurenine levels impact the ability of cells in the bone marrow to make bone-forming cells called osteoblasts. In fact, even relatively young mice fed kynurenine experience bone loss, an increase in bone destruction by cells called osteoclasts and increased fat in their bone marrow. Conversely, mice with IDO knocked out maintain strong bone mass.

"You can make an old mouse young and you can make a young mouse old," Hill noted.

The team also has evidence that part of how age-related increases in kynurenine does damage is by altering microRNAs - small but powerful pieces of RNA that can control expression of hundreds of genes at the same time - as well as vesicles called exosomes that are hauling the microRNAs around. Stem cells secrete exosomes as one way to communicate, and apparently aging stem cells don't communicate well with each other.

"Exosomes are one mechanism of crosstalk between cells and also between different organs," said Hamrick. "Your liver is producing exosomes, fat produces exosomes, they will hit other organs and they carry, in some cases, positive messages and in some cases bad messages," said Hamrick, who is leading this project to restore positive messaging.

They have laboratory evidence that aging alters at least two microRNAs, miR-141 and miR-183, which prompts cells to make bone-eating instead of bone-forming cells. Again, they have shown that even young stem cells exposed to older exosomes will assume this bone-reducing stance. But they also have some evidence that some of the dietary interventions Isales is looking at could reverse the ill effects.

The team recently reported in the journal Tissue Engineering that exosomes from old and younger mice were similar in size and number and both had a lot of miRNAs. But aged exosomes had significantly and specifically more mi183, an miRNA already associated with cancer. In this case, high mi183 appears to decrease cell proliferation and the ability of immature cells to become bone cells and to support the general deterioration that comes with age, called senescence. Age-related increases of reactive oxygen species and oxidative stress help increase mi183 levels and these undesirable results. When researchers treat mesenchymal stem cells from young animals with exosomes from old mice, is suppresses formation of muscle-making genes; giving mi183 directly to bone and muscle producing cells makes them start acting old. Now they want to know more about how aging changes the secretion and cargo of exosomes by mesynchymal stem cells and how that in turn contributes to bone and muscle loss.

A third project, led by Hill, will focus on the cargo, the miRNAs, to learn more about exactly how they impact bone formation and turnover. "We think that the amino acids are controlling the expression of specific sets of microRNA," Hill said. That means they may want to target and even eliminate key or critical microRNAs, which could obviously affect expression of numerous genes as a result.

They also are exploring aging's impact on stromal cell derived factor 1, or SDF-1, which is critical to helping keep stem cells in the bone marrow and focused on making bone. Age-related changes appear to make SDF-1 instead encourage stem cells to wander. The researchers note that while these cells do often need to leave the bone marrow, to say help heal an injury, these age-related travels are random and often cells don't find their way back. A consistent goal is identifying intervention targets.

"The idea is if we can change the environment and change how they are signaling to themselves and to other cells, we can modify the stem cell directly that way," Hill said.

They are looking upstream as well for earlier points of intervention, including what is happening to histone deacetylase-3, or HDAC3. They have evidence that HDAC3, another pervasive regulator in the body that can turn gene expression up or down, is important in stem cells' age-related propensity to make fat instead of bone.

At least one reason is that reduced HDAC3 means less bone, which literally makes more room for fat, said McGee-Lawrence, who is leading these studies. Her previous studies have shown that when HDAC3 is deleted from the skeleton, bones are weaker, much like what occurs with aging.

Now they have evidence that mice treated with kynurenine, for example, have suppressed HDAC3 expression in the bone. They want to know more about just how HDAC3 gets suppressed as we age and exactly what that does to bone formation and fat storage besides just making room. The new grant is allowing them to put the pieces together better, looking further at just what suppresses HDAC3 and what suppression does to bone versus fat formation. The bottom line again is identifying early points of intervention and potentially nutrients to intervene.

"Something in the microenvironment of the bone is causing the cells, instead of wanting to make bone, they are storing a lot of fat," McGee-Lawrence said. "Some of these epigenetic factors, like HDAC3, some of the environmental factors like changes in the amino acids are causing the cells to dysfunction. We are hoping to figure out what that signal is and how to reverse it and to make those cells want to start making bone again."

Identical twin studies have shown that environmental factors definitely play a role, since the bone/muscle health of these twins often is not identical even though their genes are, Isales said. Rather than changing the genes themselves, environmental factors appear to have changed their expression: which ones are turned or on off. These epigenetic changes include factors from diet to stress to sleep patterns to age.

There are 20 amino acids, which are essential to protein production and a variety of other functions from giving cells structure to helping organs functions. Kyrurenine also is associated with the degeneration of our brain and immune system as we age. Mesynchymal stem cells also produce blood, cartilage and fat cells.

Isales also is vice chair of clinical and translational research in the MCG Department of Orthopaedics and a faculty member in the MCG Department of Medicine. Hamrick, Hill and McGee-Lawrence are all faculty members in the MCG Department of Cellular Biology and Anatomy. Other scientists helping support three core laboratories for the interrelated studies include the Administrative Core with Biostatistics, Maribeth Johnson and Dr. Jie Chen, MCG Department of Biostatics and Epidemiology; the Bone Biology Core, Dr. Mohammed Elsalanty, Department of Oral Biology, Dental College of Georgia at AU; and the Bone Stem Cell Core, Dr. Xingming Shi, MCG Department of Neuroscience and Regenerative Medicine.

Explore further: Non-coding RNA molecule could play a role in osteoporosis

Researchers from Hong Kong Baptist University and colleagues have demonstrated that a molecule called miR-214-3p plays a role in inhibiting bone formation. MiR-214-3p is a microRNA (miRNA): a non-coding RNA involved in regulating ...

An international team of researchers, funded by Morris Animal Foundation, has shown that adipose (fat) stem cells might be the preferred stem cell type for use in canine therapeutic applications, including orthopedic diseases ...

Researchers want to turn back the clock on aging stem cells so they'll make better bone.

Adding just the right mixture of signaling moleculesproteins involved in developmentto human stem cells can coax them to resemble somites, which are groups of cells that give rise to skeletal muscles, bones, and cartilage ...

Imagine you have a bone fracture or a hip replacement, and you need bone to form, but you heal slowly a common fact of life for older people. Instead of forming bone, you could form fat. Researchers at the University ...

The prospect of regenerating bone lost to cancer or trauma is a step closer to the clinic as University of Wisconsin-Madison scientists have identified two proteins found in bone marrow as key regulators of the master cells ...

Some bodily activities, sleeping, for instance, mostly occur once every 24 hours; they follow a circadian rhythm. Other bodily functions, such as body temperature, cognitive performance and blood pressure, present an additional ...

Myelomeningocele is a severe congenital defect in which the backbone and spinal canal do not close before birth, putting those affected at risk of lifelong neurological problems. In a preclinical study published June 6th ...

Exactly when does old age begin? Which health markers best predict who will live a long and healthy life versus a life spent in poor health?

A vaccine developed at The Scripps Research Institute (TSRI) to block the "high" of heroin has proven effective in non-human primates. This is the first vaccine against an opioid to pass this stage of preclinical testing.

Yale scientists produced increased grooming behavior in mice that may model tics in Tourette syndrome and discovered these behaviors vanish when histaminea neurotransmitter most commonly associated with allergiesis ...

Delivering drugs to the brain is no easy task. The blood-brain barrier -a protective sheath of tissue that shields the brain from harmful chemicals and invaders - cannot be penetrated by most therapeutics that are injected ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original:
Major research initiative explores how our bones and muscles age, new ways to block their decline - Medical Xpress

Bone Marrow Stem Cells Comments Off on Major research initiative explores how our bones and muscles age, new ways to block their decline – Medical Xpress | June 7th, 2017

Shares of Shire (SHPG) were down $3.22 or 1.85% in early trading Wednesday to $170.88 after the company said it would transfer its U.S. investigational new drug application for for Graft-Versus-Host Disease candidate Alpha-1 Antitrypsin to Kamada (KMDA) . The treatment is aimed at addressing complications fromstem cell or bone marrow transplants.

Kamada is developing the drug in Europe. Kamada shares were down nearly 7% to $7.64.

Calithera Biosciences (CALA) was up to $16.10, a spike of 70 cents or 4.55%, after the FDA designated the company's lead product candidate, CB-839, in combination with Novartis' AFINITOR for Fast Track review for the treatment of metastatic renal cell carcinoma in patients who have received at least two prior lines of therapy.

Shares of Synergy Pharmaceutical (SGYP) rose 4.5% to $4.15 after the FDA accepted for review its supplemental New Drug Application for TRULANCE a candidate to treat irritable bowel syndrome with constipation. The FDA approved TRULANCE to treat chronic idiopathic constipation in January.

Over at Real Money, Bret Jensen looks at 4 Undervalued Biotech Stocks.

Also, Jim Cramer and the AAP team offer up stocks that will allow you to play it safe amid crazy politics.

In terms of volume, Johnson & Johnson (JNJ) and Sanofi (SNY) were among the most actively traded stocks midmorning but were both only down less than a percent.

Exact Sciences (EXAS) was trading at twice its daily volume and saw its shares fall about 6.6%, or $2.40, in early trading Wednesday to $34.19 apiece.

The Madison, Wisc.-basedmolecular diagnostics company said after markets closed on Tuesday that its underwriters, includingJefferies LLC, BofA Merrill Lynch and Robert W. Baird & Co. hadacuired7 million shares of commons stock with an option to buy about 1 million more.

Excerpt from:
Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals - TheStreet.com

Bone Marrow Stem Cells Comments Off on Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals – TheStreet.com | June 7th, 2017

Dr Bishesh Poudyal of the Civil Service Hospital in Kathmandu is the doctor who carried out all 18 transplants. At Civil the cost per transplant is between Rs 400,000 to Rs 500,000. KATHMANDU, June 7:A total of 18 bone marrow transplants have been successfully carried out in Nepal by a single doctor in Kathmandu since 2012.

A bone marrow transplant is a medical procedure performed to replace bone marrow that has been damaged or destroyed by disease, viral infection, or chemotherapy. This procedure involves transplanting blood stem cells, which travel to the bone marrow where they produce new blood cells and promote growth of new marrow.

Bone marrow is the spongy, fatty tissue inside the bones. It creates the red blood cells that carry oxygen and nutrients throughout the body, white blood cells that fight infection, and platelets that are responsible for the formation of clots.

Dr Bishesh Poudyal of the Civil Service Hospital in Kathmandu is the doctor who carried out all 18 transplants. "I am going to carry out bone marrow transplants on another six patients in near future," said Poudyal, who was born at Jawalakhel of Lalitpur.

Dr Poudyal, who passed SLC 24 years ago from Adarsha Vidya Mandir, was inspired by his father to pursue studies in hematology and bone marrow transplant. After completing his MBBS from China and MD from India under government scholarships, he started working at the Bir Hospital. "I served there for two years at Bir Hospital as per the government rule for scholarship students," he said.

Then, Dr Poudyal left the Bir Hospital as he came to know that bone marrow transplant was not possible at Bir and joined Civil Service Hospital. He also practised at the Nobel Medical College Hospital at Sinamangal where he started bone marrow transplant in 2012. "As I came to know Nobel was charging patients between Rs 800,000 to Rs 1 million per transplant, I quit the hospital," he said.

At his initiation, the Civil Hospital started bone marrow transplant about a year ago. At Civil the cost per transplant is between Rs 400,000 to Rs 500,000. The transplant recepients ranged from 22 years old to 64 years. Two patients died after about nine months of transplant. "One died of tuberculosis infection and another died of disease complications," according to Dr Poudyal.

"Bone marrow is transplanted in cancer and other blood diseases. Bone marrow is transplanted in different ways-- by treating patients' bone marrow, using siblings' and parents' bone marrow and matched unrelated donor (MUD). "We have not transplanted bone marrow under MUD category," said Dr Poudyal. "MUD is a condition of matching gene with other persons. A person's genes match those of only one percent of the population of the entire world," he added.

There is no actual data of patients with bone marrow problems in the country. However, 400 to 600 patients visit Civil Service Hospital for treatment of acute lukemia and other blood cancer cases per year. "Forty to 50 percent patients of blood cancer recover fully while the recovery rate among bone marrow recepients is 70-80 percent," said Dr Poudyal.

More:
Nepal's sole bone marrow transplant doctor - Republica

Bone Marrow Stem Cells Comments Off on Nepal’s sole bone marrow transplant doctor – Republica | June 6th, 2017

Vancouver surgeon and UBC professorRonald Lett is appealing tothe public forhelp in finding a bone marrow transplant for his wife Elizabeth Nega, who has an aggressive form of leukemia.

Nega, better known as Elsa, discovered that she had acute lymphoblasticleukemia in February and urgently needs a bone marrow transplant.However, the Ethiopian Canadian wife and mother of two has been unable to find a match because of the low number of African donors.

Ronald and Elsa are now reaching out to people of African descent to register as bone marrowdonors. They've started a website, match4elsa.com, as well as Facebook and Twitter accounts, to find Elsa and other African-Canadians life saving transplants.

"I love to live. I want to be with my kids. I want to smile again. I want to play with them again. If you save my life, you will save my whole family," said Elsa Nega in her video appeal for a donor.

Lett is the founder and international director of the charity, Canadian Network for International Surgery(CNIS). He met Elsa in Ethiopia while he was there training local doctors to perform essential surgeries.

After dedicating his life to helping others, Lett says being unable to help his wife in her time of need has been difficult.

"I helplessly watch as the love of my life suffers terribly, has devastating complications from her treatmentbut has no promise of a cure," said Lett.

"Transplant, which only works half the time, is our only hopeand all the news concerning a match for Elsahas been bad too."

Elizabeth Nega, Ronald Lett and their two children are running out of time to find Elsa a bone marrow donor. (Helen Goddard)

Since discovering that she had leukemia, Elsahas beenput through several rounds of chemotherapy, but after failing to go into remission, obtaining stem cells from a bone marrow transplant has become her only hope of recovery.

Her brother and sister in Ethiopia were her best chance, but neither were a match.

The larger issue in finding a donor for Elsa is the lack of diversity in the donor registry.

Of the 405,000 Canadians on the stem cell registry, only 800 have an African background, and none are a match for Elsa, according toChrisvan Doornwith the One Match Program.

Even among the 29 million people on the international registry, no match has been found.

Lett and Elsa's children, Lana, 8, and Lawrence, 6, have contributed to the effort.

They're in a video reading a letter appealing to Ethiopians around the world, including Canadian-Ethiopian R & B singerThe Weeknd, asking for help to save their mom.

In the meantime, Elsa's health is declining, and she's hoping for a miracle, even if it's not for her.

"If they save somebody, that's like a lotteryor a big blessing, you know.It's a big chance to get somebody to match to you and save your life.You know many people can't do this." saidNega.

People interested in registering to be a bone marrow donor can register at blood.ca,must be between 17 and 35 years old and in good health.

The test involves a cheek swab at the nearest clinicor a kit can be mailed out.

Continue reading here:
Vancouver woman's family pleading for help finding a bone marrow donor - CBC.ca

Bone Marrow Stem Cells Comments Off on Vancouver woman’s family pleading for help finding a bone marrow donor – CBC.ca | June 6th, 2017

TAMPA Researchers at the University of South Florida show in a new study that bone marrow stem cell transplants helped improve motor functions and nervous system conditions in mice with the disease amyotrophic lateral sclerosis (ALS) by repairing damage to the blood-spinal cord barrier.

In a study recently published in the journal Scientific Reports, researchers in USFs Center of Excellence for Aging and Brain Repair say the results of their experiment are an early step in pursuing stem cells for potential repair of the blood-spinal cord barrier, which has been identified as key in the development of ALS.

USF Health Professor Svitlana Garbuzova-Davis, PhD, led the project.

Using stem cells harvested from human bone marrow, researchers transplanted cells into mice modeling ALS and already showing disease symptoms. The transplanted stem cells differentiated and attached to vascular walls of many capillaries, beginning the process of blood-spinal cord barrier repair.

The stem cell treatment delayed the progression of the disease and led to improved motor function in the mice, as well as increased motor neuron cell survival, the study reported.

Read this article:
Mice with ALS improve with stem cell therapy - The Ledger

Bone Marrow Stem Cells Comments Off on Mice with ALS improve with stem cell therapy – The Ledger | June 6th, 2017

Paul Spagnuolo is working on creating a drug with an avocado compound that targets cancer cells. (Paul Spagnuolo)

A Guelph food science researcher is getting $100,000 from the Ontario Institute for Cancer Research to fund investigations into using an avocado compound as a possible treatment for leukemia.

Paul Spagnuolo discovered that Avocatin B, a compound mainly found in avocado pits can kill leukemia stem cells in 2015.

"Getting funds to do any type of research is a reason to celebrate," said Spagnuolo told CBC News.

The funding will further his research by allowing his lab to use better equipment and collaborate with cancer researchers from the University of Toronto, Princess Margaret Cancer Centre, Ottawa University and McMaster University.

Spagnuolo's lab tested more than 800 natural compounds for their ability to kill leukemia stem cells and discovered Avocatin B was the most potent and only targetedcancer cells.

Avocatin B kills leukemia stem cells by stopping fatty acid oxidation in the cells, a process necessary for the cancer cell to digest fat as a fuel source in order to live and grow.

"Our cells can utilize glucose primarily and some other parts, but leukemia cells are rewired so that if you inhibit the oxidation process, they will die," he said.

Spagnulo and his lab are now looking to develop a way to detect whether or not Avocatin B is circulating in the blood and bone marrow.

Leukemia cells live in the bloodstream or bone marrow, so it's important for the drug to make it to those parts to kill the cancer cells.

"We want to be able to detect our drug inside the blood so that we can understand how we can formulate products better to get our product into the blood," said Spagnuolo.

Moving forward, Spagnuolo's lab will have to report to OICR quarterly, it's a condition of the funding which is spread over two years and has the possibility of renewal for another two years.

"(It's) a lot more intense than I anticipated, but I think the key here is it's very results oriented," said Spagnuolo, "There's no complacency here."

Read the rest here:
Pitting avocados against leukemia stem cells - CBC.ca

Bone Marrow Stem Cells Comments Off on Pitting avocados against leukemia stem cells – CBC.ca | June 6th, 2017

Multiple myeloma is cancer that involves our bone marrow with a specific cell called a plasma cell that patients can develop. Most patients will need a bone marrow transplant.

Patients needing bone marrow transplants dont have to travel far to receive this potentially life-saving transplant.

The actual day of the diagnosis was November 18th of 2015 and it was a diagnosis for multiple myeloma, said Steven Simpson.

Simpson was ready to fight from that day on. He learned from Dr. Kelly McCaul, the director of Avera Hematology Transplant Program, that he would need a bone marrow transplant.

There are many different types of transplant that we do. Theres basically an autologous transplant where patients would be their own donors for their stem cells and then theres allogenic transplant which are some sort of donor process. And so Steve has multiple myeloma. We would normally look at autologous transplant as the preferred pathway for patients with that disease, said Dr. McCaul.

Weve never had to leave anywhere other than here. This is it, said Simpson.

Simpson and his immediate family live no further than 20 minutes away from Avera McKenna so getting the transplant elsewhere was out of the question. But that didnt come without resistance from his insurance company.

Youre asking somebody to go three or four hours out of the way minimum for a period of time that could last anywhere from a week to whatever the process is. You lose your doctors. You lose the ability to have any local family support there as you need them and you dont really know what youre getting into. You just know what youre told, said Simpson.

Simpson and his insurance company worked together and was able to stay at Avera for his transplant.

I came in the day before scheduled for the transplant but left three hours after the transplant because I didnt have any reactions. Plus, we all knew that I had somebody available to watch me 24/7 for the period of time that we would have. The fact that you have your doctors here, your oncologist, your lab people, your nursing staff, everybodys here. They know who you are, said Simpson.

17 years ago when I first looked at this program one of the big things I looked at was the need in the community and it was felt from my perspective, and obviously Avera, that our need in the community was high. And it allows patients to stay within the community, close to family members, without having to drive four, five hours away, said Dr. McCaul.

Today, Simpson is well on his way to feeling like his old self, something he credits to staying close to home for his transplant.

For more information just call 877-AT-AVERA

Originally posted here:
Bone marrow transplant patient credits positive recovery to staying close to home - KSFY

Bone Marrow Stem Cells Comments Off on Bone marrow transplant patient credits positive recovery to staying close to home – KSFY | June 5th, 2017

As a third grade teacher at Ottawa Elementary School, Kelly Gianotti teaches students many important life lessons along with reading and math.

The most important lesson she has instructed was taught by example: how to save the life of a blood cancer patient.

Gianotti donated her stem cells in 2013 to help save the life of a blood cancer patient. The patient was in need of a bone marrow stem cell transplant and had no donor match in her family.

I had seen a flier at a local gym for a high school student who was looking for a match. That intrigued me. I went online to register, Gianotti said.

Advertisement

A year later Gianotti learned she was a potential match, but not for the high school patient. She went through more testing and did the outpatient donation procedure.

Gianotti later found out her donation assisted MaryAnn Hastings, who lived near Boston, Mass. The two chatted via e-mail and were able to meet in 2016, when Gianotti traveled to Boston.

The lady I donated for died last February of a different type of cancer. I wanted to honor her and spread the word, Gianotti said, adding that Hastings family indicated she was able to give Hastings three extra years of life with her donation.

The donation experience motivated Gianotti to host the first DKMS bone marrow registration drive through Chippewa Valley Schools district. DKMS is an international nonprofit organization dedicated to the fight against blood cancer and blood disorders, according to its website.

The goal of the drive is to help register potential donors. It will be held Tuesday from 4 p.m. to 9 p.m. at Cheyenne Elementary School in Macomb Township. Gianotti said she hopes to register between 100 and 200 potential donors.

Requirements to join the bone marrow registry are that the donor be in good health and between the ages of 18 and 55. The process involves filling out a form, understanding the donation methods and swabbing the inside of each cheek for 30 seconds with a cotton swab. Donors swab their cheeks in a circular motion.

There is no cost to register, although donations are accepted. The donations assist DKMS in covering the $65 registration processing fee.

According to DKMS, 70 percent of people suffering from blood-related illnesses rely on donors other than their families.

If selected as a match for a patient, there are two different methods of donation, according to the DKMS website.

According to the DKMS website, a donation method used in about 25 percent of cases is a one or two hour surgical procedure performed under anesthesia to collect marrow cells from the back of the pelvic bone using a syringe.

To obtain more information about the drive or to make a monetary donation, visit fb.com/cvsgetsswabbed. Those who want to join the bone marrow registry but are unable to attend the June 6 drive can register at dkms.org.

The rest is here:
Chippewa Valley Schools hosts bone marrow registration drive - The Macomb Daily

Bone Marrow Stem Cells Comments Off on Chippewa Valley Schools hosts bone marrow registration drive – The Macomb Daily | June 5th, 2017

COUNTLESS lives across the world could be saved by an Oxfordshire familys appeal to find a bone marrow donor for their little boy.

Two-year-old Alastair Ally Kim has Chronic Granulomatous Disorder (CGD), a life-threatening condition.

He has now become the fourth person in the world to start an experimental gene therapy course at Great Ormond Street Hospital.

In the meantime, his parents have spearheaded 200 international donor drives to find their son a match, signing up 7,000 would-be donors in the process - some of whom have since been matched with other patients.

Father Andrew Kim, 37, of Hinton Waldrist near Longworth, said: We want to use whatever momentum Allys story has to help someone else. We know that matches have come through our drives for other people. Its awesome that someone will benefit from all this.

On Thursday, May 25 family friend Cathy Oliveira organised a drive at the Oxford Universitys Old Road research building, signing up 80 staff members in a day.

Ms Oliveira said: When everything happened with Ally I wanted to show support in any way we could; this is directly beneficial not just for Ally but for others.

Allys CGD means his immune system is compromised and the tiniest infection could leave him seriously ill.

His only chance of a permanent cure is a bone marrow stem cell donation, with a match likely to be of Korean or East Asian origin.

In April the youngster and mum Judy Kim, 36, an Oxford University researcher, travelled to London for him to begin a pioneering new gene therapy treatment.

After a week of chemotherapy to wipe out Allys immune system, cells taken from him are modified in a lab and re-introduced to correct the disorder.

Mr Kim said: Bone marrow would give him back 100 per cent functionality and gene therapy is 10 to 15 per cent; its enough to live in the real world, and not be scared he will die every time he gets an infection.

It has been a roller-coaster of a year, but theres nothing to do but move forward. We are really excited at the thought of him being able to come home this summer.

Blood cancer charity DKMS supported last weeks donor drive in Oxford.

Senior donor recruitment manager Joe Hallet said: Around 30 per cent of patients in need of a blood stem cell donor will find a matching donor within their own family.

The remaining 70 per cent, like Ally, will need to find an unrelated donor to have a second chance of life, so events like these are crucial.

View original post here:
Oxford University staff join bone marrow stem cell donor drive for Oxford toddler Ally Kim - Witney Gazette

Bone Marrow Stem Cells Comments Off on Oxford University staff join bone marrow stem cell donor drive for Oxford toddler Ally Kim – Witney Gazette | June 3rd, 2017